Seres Therapeutics, Inc. Revenue 2015–2025
Seres Therapeutics, Inc. annual/quarterly revenue history and growth rate from 2015 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Seres Therapeutics, Inc. revenue for the quarter ending March 31, 2026 was 358000.
- Seres Therapeutics, Inc. revenue for the twelve months ending March 31, 2026 was 709000, a 99.44% decrease year-over-year.
- Seres Therapeutics, Inc. annual revenue for 2025 was 789000.
- Seres Therapeutics, Inc. annual revenue for 2024 was 0.
- Seres Therapeutics, Inc. annual revenue for 2023 was 0, a 100.00% decrease from 2022.
- Seres Therapeutics, Inc. annual revenue for 2022 was 7.1 M.
Seres Therapeutics, Inc. (MCRB) — Frequently Asked Questions
Seres Therapeutics, Inc. (MCRB) is a publicly traded US company. It has a market capitalization of $58M. In fiscal 2025 it reported revenue of $789,000 and net income of $6M. Explore MCRB's stock price, financial statements, earnings history, margins and key ratios below.
What is Seres Therapeutics, Inc.'s market cap?
Seres Therapeutics, Inc. (MCRB) has a market capitalization of $58M.
What is the MCRB stock price?
MCRB trades at $6.49 (+2.53% on the day).
How much revenue does Seres Therapeutics, Inc. make?
Seres Therapeutics, Inc. reported revenue of $789,000 in fiscal 2025.
Is MCRB profitable?
In fiscal 2025, Seres Therapeutics, Inc. reported net income of $6M.